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Abstract
Background: The main goal when managing patients with inoperable oesophageal cancer is to
restore and maintain their oral nutrition. The aim of the present study was to assess the value of
endoscopic palliation of dysphagia in patients with oesophageal cancer, who either due to advanced
stage of the disease or co-morbidity are not suitable for surgery.
Patients and methods: All the endoscopic palliative procedures performed over a 5-year period
in our Unit were retrospectively reviewed. Dilatation and insertion of self-expandable metal stents
(SEMS) were mainly used for tight circumferential strictures whilst ablation with Nd-YAG laser was
used for exophytic lesions. All procedures were performed under sedation.
Results: Overall 249 palliative procedures were performed in 59 men and 40 women, with a
median age of 73 years (range 35 – 93). The median number of sessions per patient was 2 (range
1 – 13 sessions). Palliation involved laser ablation alone in 24%, stent insertion alone in 22% and
dilatation alone in 13% of the patients. In 41% of the patients, a combination of the above palliative
techniques was applied. A total of 45 SEMS were inserted. One third of the patients did not receive
any other palliative treatment, whilst the rest received chemotherapy, radiotherapy or
chemoradiotherapy. Swallowing was maintained in all patients up to death. Four oesophageal
perforations were encountered; two were fatal whilst the other two were successfully treated with
covered stent insertion and conservative treatment. The median survival from diagnosis was 10.5
months (range 0.5–83 months) and the median survival from 1st palliation was 5 months (range 0.5–
68.5 months).
Conclusion: Endoscopic interventions are effective and relatively safe palliative modalities for
patients with oesophageal cancer. It is possible to adequately palliate almost all cases of malignant
dysphagia. This is achieved by expertise in combination treatment.
Background
Oesophageal cancer is a relatively rare disease. The aver-
age age standardised incidence rate in the EU for the year
2004, was 9.5 per 100,000 of male population and 8.7 per
100,000 of female population [1]. Patients with oesopha-
geal cancer and cancer of the gastro-oesophageal junction
(GOJ) commonly present with advanced disease mainly
because the oesophagus is quite distentable and patients
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may not experience dysphagia until almost half of the
luminal diameter is compromised. At least 60% of
patients with oesophageal cancer will be unsuitable for
surgical resection either due to the stage of their disease or
due to co-morbidity [2,3]. A large proportion of patients
treated surgically, on the other hand, despite curative
intention will turn out to have undergone a palliative
resection [4]. The mean survival in these patients is only 4
– 6 months and the aim of their management is to
improve the quality of life with palliative treatment.
Dysphagia is the most devastating symptom and is classi-
fied into four grades of severity [2]. Aspiration is another
frequent symptom requiring palliative therapy. This is
either aspiration of saliva as a result of complete dys-
phagia or food aspiration due to a tracheo-oesophageal
fistula.
Palliative bypass surgery, which was widely performed
until the late 80's, has been discounted because of its high
mortality rates in the range of 20–35% [5,6]. Nowadays,
main palliative modalities include radiotherapy, endolu-
minal ablative therapies and insertion of endoprostheses
[3,5,7-12]. This study looked specifically at the modalities
of laser ablation and self-expanding metal stents (SEMS).
The aim was to assess the value and effectiveness of these
procedures in palliation of malignant dysphagia.
Patients and methods
We retrospectively reviewed all the endoscopic palliative
procedures performed in our Unit between January 1999
and December 2003. Overall 249 palliative procedures
were performed in 99 patients, 59 men and 40 women,
with a median age of 73 years (range 35–93 years). The
characteristics of the tumours, the degree of dysphagia,
the type of palliation, the complications and the overall
survival were recorded.
In patients with short strictures, a mild dilatation of the
malignant stricture to 12–14 mm with flexible rubber
Savary-Guillard dilators was performed as the primary
palliative treatment. The insertion of a self-expandable
metal stent (SEMS) was mainly used for long tight circum-
ferential strictures and in strictures that did not respond to
other type of palliative treatment. In very frail patients a
SEMS was often applied as the single palliative modality.
Other indications for SEMS insertion were cases of
oesophageal perforation. The type of SEMS used in this
series was the Ultraflex (Boston Scientific, MA, USA). This
stent is constructed of a single strand of nitilol wire that
exerts a constant, gentle radial pressure while minimising
traumatic tissue compression and comes in a range of
lengths (7–15 cm) and diameters (17–22 mm). These
stents are available with both proximal-release and distal-
release deployment systems. In our practice, proximal-
release stents were used for strictures of the middle and
upper oesophagus whilst distal-release stents were used
for strictures of the gastro-oesophageal junction. All the
stents were inserted under endoscopic control.
Endoluminal ablation with neodymium-yttrium-alumi-
num-garnet (Nd-YAG) laser was mainly used for exo-
phytic lesions or short strictures (Sharlan 2100, Litechnica
Ltd, Middlesex, UK). Laser output was set at 60 – 90 W and
1- to 2-second pulses were delivered to the tumour. Laser
ablation was performed with the retrograde approach i.e.
from distally to proximally. The total amount of energy
varied according to the local conditions and the patient's
tolerance.
More than one session and combination of techniques
was often necessary. All the procedures were performed
under sedation. The sedation protocol included intrave-
nous administration of diazepam emulsion preparation 5
mg/ml (Diazemuls). Oxygen was also administered and
monitoring during the procedure comprised pulse oxym-
etry. The vast majority of cases were performed as day
cases and the patient after recovery was sent home with
appropriate instructions.
Results
There were 3 upper third, 22 middle third, 41 lower third
oesophageal tumours and 33 GOJ tumours. Sixty-three of
these tumours were adenocarcinomas, 35 were squamous
cell carcinomas and a GOJ tumour was a lymphoma.
According to Müller's classification, 36 patients had grade
1 dysphagia, 29 had grade 2, 22 had grade 3 and 12
patients had grade 4 dysphagia. The patients of the
present study were unsuitable for surgery either due to
comorbidities or due to the stage of their disease. Figure 1
shows the patients' ASA classification and figure 2 shows
the stage of their disease.
Overall 249 palliative procedures were performed. The
median number of palliative endoscopic sessions per
patient was 2 (range 1 – 13 sessions). In 13 patients
(13%) one or more dilatations were used as the single pal-
liative modality. Palliation involved laser ablation alone
in 24% and stent insertion alone in 22% of the patients.
In 41% of the patients, a combination of the above palli-
ative techniques was applied (Fig. 3). A total of 45 SEMS
were inserted with a median length of 12 cm (range 9 – 15
cm). Treatment involved laser ablation in 61 patients with
a median energy of 2442 Joules per session (range 60 –
10991 Joules). Two thirds of the patients were also given
non-endoscopic palliative treatment for controlling the
tumour in the form of chemotherapy, radiotherapy or
chemoradiotherapy (Fig. 4). The radiotherapy in all
patients was external beam irradiation.World Journal of Surgical Oncology 2006, 4:38 http://www.wjso.com/content/4/1/38
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In 24 patients that laser ablation was used as mono-
therapy, the time interval between sessions was usually 4–
6 weeks depending on the response and the patient's sta-
tus. In other 16 patients, however, where despite repeti-
tion of Nd-YAG laser ablation treatment dysphagia
persisted, a SEMS was eventually placed. The median
number of laser treatment sessions before insertion of
SEMS in this group of patients was 2 (range 1 – 5 ses-
sions).
Swallowing was maintained in all patients up to death.
Four oesophageal perforations were encountered; two
were fatal whilst the other two were successfully treated
with covered stent insertion and conservative treatment.
The first of sthe fatal perforations followed a dilatation of
a tight GOJ tumour to 14 mm. The second fatal perfora-
tion followed laser ablation of a middle oesophageal
tumour. Both patients developed severe mediastinitis and
deteriorated rapidly. Due to their terminal disease and
frailty further interventions were deemed inappropriate
and they were kept comfortable until their death.
Another oesophageal perforation was caused during dila-
tation of a very tight GOJ tumour to 12 mm. On reinspec-
Other type of non-endoscopic palliative therapy was also  used in 2/3 of patients Figure 4
Other type of non-endoscopic palliative therapy was also 
used in 2/3 of patients.
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Stage of oesophageal carcinoma Figure 2
Stage of oesophageal carcinoma.
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ASA score of patients Figure 1
ASA score of patients.
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Endoscopic modalities used to palliate dysphagia Figure 3
Endoscopic modalities used to palliate dysphagia.
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tion a posterior oesophageal rupture was seen and a
covered SEMS was immediately placed. Lastly, there was a
suspected small perforation during a SEMS placement for
a lower third oesophageal tumour. Both these patients
were treated conservatively and commenced oral intake a
few days later after a gastrograffin swallow test.
A patient with severe ischaemic heart disease died from
myocardial infarction on day 6 following the insertion of
a SEMS. Two further patients died of their disease within
a month following a session of endoscopic intervention.
These deaths, however, should not be considerd related to
the procedure that was performed.
In two patients the session of laser ablation treatment had
to be terminated due to uncontrolled coughing fit and was
postponed to a later date.
Problems related to the placement of SEMS were food
bolus impaction and occlusion of the stent in 5 patients,
excessive tumour ingrowth in 6 patients and encroach-
ment of stent over GOJ in one patient. The blockage was
treated according to the local conditions with either just
balloon dilatation or laser treatment. In two of these
patients local recurrence of the tumour occluded the
lumen almost completely and a new stent had to be
placed. Lastly, there was a case of persisting dysphagia fol-
lowing the placement of a stent, despite free contrast flow
on barium meal. It was assumed that this type of func-
tional dysphagia was a result of neuromuscular dysfunc-
tion secondary to tumour infiltration.
The median survival from diagnosis was 10.5 months
(range 0.5 – 83 months) and the median survival from 1st
palliation was 5 months (range 0.5 – 68.5 months).
The median time from diagnosis to first palliation was 3
months (range 0 – 47.5 months).
Discussion
The main goal when managing patients with inoperable
oesophageal and junctional cancer is to restore and main-
tain their oral nutrition. Furthermore, aims of palliation
should also be minimizing the hospital stay, relief of pain,
elimination of reflux and regurgitation, and the preven-
tion of aspiration [7]. A variety of options to palliate dys-
phagia have been developed and evolved in recent years
[3,5,7-12]. The choice for palliation for a particular
patient will depend on tumour size and location, the
experience of the operator and the resources available at
the health care institution.
Since 1999 in our practice at Mount Vernon Centre for
Cancer, palliative modalities for malignant dysphagia
include insertion of SEMS and endoluminal ablation with
Nd-YAG laser.
SEMS were introduced in the early 1990s and have nowa-
days superseded conventional endoluminal oesophageal
prostheses despite their high cost which is at the range of
£700–800. Their major advantages are ease of placement,
immediate relief and low perforation risk as compared to
conventional prostheses. Potential problems related to
SEMS may be migration of the stent, food bolus impac-
tion, gastro-oesophageal reflux and tumour ingrowth into
the stent mesh or around the ends of the stent. In our
series food occluded the stent in 5 patients and tumour
ingrowth occurred in 6 patients. Gastro-oesophageal
reflux was an issue in a few cases of GOJ stents; however
all patients responded well to treatment with proton
pump inhibitors (PPIs). No stent migration or other
delayed complication occurred.
The introduction of endoluminal tumour ablation with
Nd-YAG laser for exophytic oesophageal or GOJ malig-
nancies was at one time a major advance in therapeutic
endoscopy as it dramatically reduced the number of con-
ventional oesophageal prostheses placed. Endoluminal
tumour ablation with Nd-YAG laser provides immediate
dysphagia relief but has limited durability (weeks) if not
followed by adjuvant therapy [8]. We usually repeat abla-
tion every 4–6 weeks. From technical point of view, we
use the retrograde approach and find it effective and safe.
Mitty et al [9] reported the treatment of 62 patients with
Nd-YAG laser ablation and concluded that the retrograde
approach allowed fewer treatment sessions, the treatment
of longer lesions, greater improvement in dysphagia and
reduced the risk of aspiration.
This was a retrospective study with all its inherent short-
comings. Our results showed that the use of one or a com-
bination of these interventions enabled swallowing to be
maintained in all patients until death. We could not, how-
ever, quantify in retrospect the improvement of dysphagia
and to assess the impact on the patients' quality of life.
The choice of the most appropriate treatment at every ses-
sion should be tailored to the type of stricture and the
patient's condition. In this series, the insertion of SEMS
was mainly used for long tight circumferential strictures
and in strictures that did not respond to other type of pal-
liative treatment. In very frail patients SEMS placement
was often applied as the single palliative modality. Endo-
luminal ablation with Nd-YAG laser was mainly used for
exophytic lesions or short strictures. In 24 patients laser
ablation was used as monotherapy effectively. In other 16
patients, however, where despite repetition of laser treat-
ment dysphagia persisted, a SEMS was eventually placed.
The number of laser ablation sessions and the amount ofPublish with BioMed Central    and   every 
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energy required varied and the eventual decision of a stent
placement relied both upon the response and the patient's
status.
Another issue is dealing with problems that may ensue
after placement of a stent. The operator has to be able to
tackle proficiently a variety of conditions including com-
plications using a combination of techniques. In the
present series occlusion of the stent either due to food
impaction or due to tumour local overgrowth was treated
according to the local conditions with balloon dilatation
or laser ablation and in two cases with insertion of an
extra stent.
This study has also shown that endoscopic interventions
can be performed as day case procedures under sedation,
providing that hospital backup is readily available.
Overall survival in this study did not significantly differ
from figures in the literature whereas complication rates
were much lower than previously reported in other series
[9,10,12]. Palliation of malignant strictures involves spe-
cialized procedures and therefore expertise developed in
regional centres, which could minimize complication
rates [7].
Conclusion
It is possible to adequately palliate almost all cases of
malignant dysphagia. This is achieved by expertise in
combination treatment. Palliation of malignant dys-
phagia by the use of laser ablation and SEMS insertion is
effective and relatively safe. The management of patients
with oesophagogastric cancer, who are not suitable for
surgery, requires a multidisciplinary approach in special-
ised cancer centres.
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